HK Stock Market Move | LEPU BIO (02157) surged over 5% in the afternoon, with a 12.1% year-on-year increase in revenue for the first half of the year, and is about to complete the entire BD value chain for CMG901.

LEPU BIO (02157) rose over 5% in the afternoon, and as of the time of writing, it had increased by 3.9%, reaching HKD 4.13, with a transaction volume of HKD 81.1136 million. In recent news, LEPU BIO announced its performance for the six months ending June 30, 2026, with revenue of RMB 522 million, a year-on-year increase of 12.1%; the profit attributable to shareholders was RMB 27.393 million, down 34.4% year-on-year; basic earnings per share were RMB 0.02. Regarding domestic commercialization, the group reported sales revenue from Mei You Heng (Vibekotamab Injection) and Pu You Heng (Putilizumab Injection) of approximately RMB 371.3 million, which is more than double the sales achieved in the same period of 2025 (six months ending June 30, 2025: RMB 150.6 million). Guolian Minsheng Securities released a research report stating that LEPU BIO licensed global rights for CMG901 to AstraZeneca and licensed MRG007 outside of Greater China to ArriVent, realizing the monetization of its research and development capabilities. During the reporting period, the company confirmed milestone revenue from the license agreements for CMG901 and MRG007 totaling RMB 149 million. In terms of business model, the company has successfully built and validated its domestic commercialization capabilities, while also about to streamline the full BD chain for CMG901. This marks LEPU BIO's ability to continuously optimize its revenue structure through a dual-driven approach of domestic commercialization and overseas licensing.